EBOS Group has completed its four-year, A$360 million distribution centre renewal program, marking a significant inflection point for the company’s capital allocation strategy. The investment cycle completion removes a substantial drag on cash flow, with capital expenditure expected to decline to approximately A$100 million in FY27 from A$145 million in FY26, potentially releasing more than A$150 million for growth investments and shareholder returns.
The group delivered FY26 results in line with guidance, with underlying EBITDA rising 5.0 percent to A$614 million despite material headwinds from fuel costs and foreign exchange impacts. Revenue grew 9.9 percent to A$13.5 billion, with both Healthcare and Animal Care segments demonstrating resilience. The completion of the DC renewal network has begun to yield productivity gains, particularly at the new Kemps Creek facility, which is targeting approximately 30 percent improvement in warehouse productivity by FY27.
Underlying net profit after tax declined 3.1 percent to A$250 million, reflecting higher depreciation and amortisation costs associated with the investment cycle and increased financing costs, a deliberate trade-off management accepted to modernise the network and position for future growth. Leverage remained within the company’s 1.7x to 2.3x target range at 2.1x, providing headroom for further debt-funded acquisitions or capital returns.
Management signalled clear execution priorities for FY27, guiding to underlying EBITDA of A$635 million to A$655 million, representing mid-single digit organic growth. Healthcare expects to maximise new distribution capacity and capture increased funding for specialty medicines, while Animal Care is focused on premiumisation through new fresh and chilled product formats following the Paringa acquisition. Medical Technology aims to expand geographic reach and therapy areas through additional partnerships and bolt-on M&A.
The shift from heavy capital deployment to organic growth initiatives and strategic acquisitions should drive improved free cash flow generation. Dividend policy remained unchanged at a payout ratio targeting 60 to 80 percent of underlying net profit after tax. The capital intensity reduction and improved cash generation may create additional capacity for returns if management executes efficiently on its growth pipeline.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARInvestors should monitor whether EBOS deploys its available acquisition capital productively and whether the DC network productivity gains materialise as forecast. The group’s track record of disciplined bolt-on M&A and ability to integrate assets will determine whether the completion of the investment cycle translates into sustainable earnings acceleration and improved returns on the capital deployed.
View the full ASX announcement (PDF)
About EBOS Group Limited (ASX: EBO)
EBOS Group Limited is the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company provides pharmaceutical and wellness products to community pharmacies, hospitals, and healthcare facilities, and also operates an animal health product wholesale and retail business. The company is headquartered in Docklands, Australia and generates the majority of its revenue from pharmaceutical distribution services to community pharmacies and institutional healthcare providers.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
Learn to trade with a plan
Our free 5-day course covers entries, exits and risk management.
Start the free courseBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR